{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:36:15Z","timestamp":1793975775970,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This case study was made possible by philanthropic support from the family and friends of Louis Stephen Zuzga Moran and the family and friends of Douglas B. Janney, Jr."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report the case of a 79-year-old woman with Alzheimer\u2019s disease who participated in a Phase III randomized controlled trial called CLARITY-AD testing the experimental drug lecanemab. She was randomized to the placebo group and subsequently enrolled in an open-label extension which guaranteed she received the active drug. After the third biweekly infusion, she suffered a seizure characterized by speech arrest and a generalized convulsion. Magnetic resonance imaging revealed she had multifocal swelling and a marked increase in the number of cerebral microhemorrhages. She was treated with an antiepileptic regimen and high-dose intravenous corticosteroids but continued to worsen and died after 5 days. Post-mortem MRI confirmed extensive microhemorrhages in the temporal, parietal and occipital lobes. The autopsy confirmed the presence of two copies of APOE4, a gene associated with a higher risk of Alzheimer\u2019s disease, and neuropathological features of moderate severity Alzheimer\u2019s disease and severe cerebral amyloid angiopathy with perivascular lymphocytic infiltrates, reactive macrophages and fibrinoid degeneration of vessel walls. There were deposits of \u03b2-amyloid in meningeal vessels and penetrating arterioles with numerous microaneurysms. We conclude that the patient likely died as a result of severe cerebral amyloid-related inflammation.<\/jats:p>","DOI":"10.1038\/s41467-023-43933-5","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T05:09:29Z","timestamp":1702357769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-0368","authenticated-orcid":false,"given":"Elena","family":"Solopova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9868-8074","authenticated-orcid":false,"given":"Wilber","family":"Romero-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Ventura-Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Shostak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-7059","authenticated-orcid":false,"given":"Jose","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manus J.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1412-1463","authenticated-orcid":false,"given":"Daniel","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Charidimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-0503","authenticated-orcid":false,"given":"Matthew","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"43933_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nm0302-199b","volume":"8","author":"K Birmingham","year":"2002","unstructured":"Birmingham, K. & Frantz, S. Set back to Alzheimer vaccine studies. Nat. Med. 8, 199\u2013200 (2002).","journal-title":"Nat. Med."},{"key":"43933_CR2","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll, J. A. R. et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer\u2019s disease. Brain 142, 2113\u20132126 (2019).","journal-title":"Brain"},{"key":"43933_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2015.4078","volume":"73","author":"E Auriel","year":"2016","unstructured":"Auriel, E. et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 73, 197\u2013202 (2016).","journal-title":"JAMA Neurol."},{"key":"43933_CR4","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"43933_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani, R. J. et al. Neuropathology of anti-amyloid-\u03b2 immunotherapy: a case report. J. Alzheimers Dis. 93, 803\u2013813 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"43933_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"N Reish","year":"2023","unstructured":"Reish, N. et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N. Engl. J. Med. 388, 478\u2013479 (2023).","journal-title":"N. Engl. J. Med."},{"key":"43933_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund, L. O. et al. A new rating scale of age-related white matter changes applicable to MRI and CT. Stroke 32, 1318\u20131322 (2001).","journal-title":"Stroke"},{"key":"43933_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1212\/WNL.56.4.537","volume":"56","author":"KA Knudsen","year":"2001","unstructured":"Knudsen, K. A., Rosand, J., Karluk, D. & Greenberg, S. M. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56, 537\u2013539 (2001).","journal-title":"Neurology"},{"key":"43933_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou, A. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 21, 714\u2013725 (2022).","journal-title":"Lancet Neurol."},{"key":"43933_CR10","doi-asserted-by":"publisher","first-page":"e1009406","DOI":"10.1371\/journal.pgen.1009406","volume":"17","author":"AG Nackenoff","year":"2021","unstructured":"Nackenoff, A. G. et al. PLD3 is a neuronal lysosomal phospholipase D associated with beta-amyloid plaques and cognitive function in Alzheimer\u2019s disease. PLoS Genet. 17, e1009406 (2021).","journal-title":"PLoS Genet."},{"key":"43933_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00401-009-0615-z","volume":"119","author":"M Schrag","year":"2010","unstructured":"Schrag, M. et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol. 119, 291\u2013302 (2010).","journal-title":"Acta Neuropathol."},{"key":"43933_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367\u2013385 (2011).","journal-title":"Alzheimers Dement."},{"key":"43933_CR13","doi-asserted-by":"crossref","unstructured":"Roher, A. et al. Bapineuzumab alters A\u03b2 composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS ONE 8, e59735 (2023).","DOI":"10.1371\/journal.pone.0059735"},{"key":"43933_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JAD-2011-101809","volume":"24","author":"A Roher","year":"2011","unstructured":"Roher, A. et al. Neuropathology and amyloid-\u03b2 spectrum in a bepineuzumab immunotherapy recipient. J. Alzheimers Dis. 24, 315\u2013325 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"43933_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"43933_CR16","doi-asserted-by":"publisher","unstructured":"Sims J. R. et al. Donanemab in early symptomatic Alzheimer disease. JAMA https:\/\/doi.org\/10.1001\/jama.2023.13239 (2023).","DOI":"10.1001\/jama.2023.13239"},{"key":"43933_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/ene.14031","volume":"26","author":"K Sakai","year":"2019","unstructured":"Sakai, K. et al. Nationwide survey of cerebral amyloid angiopathy in Japan. Eur. J. Neurol. 26, 1487\u20131493 (2019).","journal-title":"Eur. J. Neurol."},{"key":"43933_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrneurol.2011.222","volume":"8","author":"P Scheltens","year":"2012","unstructured":"Scheltens, P. & Goos, J. D. Dementia in 2011: microbleeds in dementia-singing a different ARIA. Nat. Rev. Neurol. 8, 68\u201370 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"43933_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jalz.2011.05.2352","volume":"7","author":"RJ Schindler","year":"2011","unstructured":"Schindler, R. J. & Carrillo, M. C. Output of the working group on magnetic resonance imaging abnormalities and treatment with amyloid-modifying agents. Alzheimers Dement. 7, 365\u2013366 (2011).","journal-title":"Alzheimers Dement."},{"key":"43933_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway, S. et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79, 13\u201321 (2022).","journal-title":"JAMA Neurol."},{"key":"43933_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll, J. A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448\u2013452 (2003).","journal-title":"Nat. Med."},{"key":"43933_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer, I., Boada Rovira, M., Sanchez Guerra, M. L., Rey, M. J. & Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer\u2019s disease. Brain Pathol. 14, 11\u201320 (2004).","journal-title":"Brain Pathol."},{"key":"43933_CR23","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1212\/WNL.0000000000005060","volume":"90","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology 90, e877\u2013e886 (2018).","journal-title":"Neurology"},{"key":"43933_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"43933_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3233\/JAD-160981","volume":"57","author":"E Heuer","year":"2017","unstructured":"Heuer, E. et al. Amyloid-related imaging abnormalities in an aged squirrel monkey with cerebral amyloid angiopathy. J. Alzheimers Dis. 57, 519\u2013530 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"43933_CR26","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","volume":"9","author":"W Zago","year":"2013","unstructured":"Zago, W. et al. Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9, S105\u2013S115 (2013).","journal-title":"Alzheimers Dement."},{"key":"43933_CR27","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves, F., Kallinowski, P. & Ayton, S. Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and meta-analysis. Neurology 100, e2114\u2013e2124 (2023).","journal-title":"Neurology"},{"key":"43933_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jamaneurol.2023.0815","volume":"80","author":"V Planche","year":"2023","unstructured":"Planche, V. & Villain, N. Advocating for demonstration of disease modification - have we been approaching clinical trials in early Alzheimer disease incorrectly? JAMA Neurol. 80, 659\u2013660 (2023).","journal-title":"JAMA Neurol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43933-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43933-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43933-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T05:14:08Z","timestamp":1702358048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43933-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43933"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-43933-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2865642\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.D. receives research-related support from Philips North America; is a paid consultant for Pfizer Inc, Alterity, Global Blood Therapeutics, Graphite Bio, and LymphaTouch; is a paid advisory board member for Novartis and Bluebird Bio; receives research funding from Pfizer Inc; and is the President\/CEO of Biosight, LLC, which operates as a clinical research organization. A.C. reports receiving funding from the Bodossaki Foundation and the Frechette Family Foundation and consulting fees from Imperative Care. M.S. reports receiving funding from the American Federation of Aging Research, the National Institutes of Health, and consulting fees from Labaton-Sucharow LLP and Raymond James. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8220"}}